Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): A phase 3, randomised controlled trial

The Lancet Oncology

Volumn 17, Issue 3, 2016, Pages 309-318

  Fujitani, Kazumasa ^a   Yang, Han Kwang ^b   Mizusawa, Junki ^c   Kim, Young Woo ^d   Terashima, Masanori ^e   Han, Sang Uk ^f   Iwasaki, Yoshiaki ^g   Hyung, Woo Jin ^h   Takagane, Akinori ⁱ   Park, Do Joong ^b   Yoshikawa, Takaki ^j   Hahn, Seokyung ^b   Nakamura, Kenichi ^c   Park, Cho Hyun ^k   Kurokawa, Yukinori ^l   Bang, Yung Jue ^b   Park, Byung Joo ^b   Sasako, Mitsuru ^m   Tsujinaka, Toshimasa ⁿ  

^a Department of Paediatrics   (Japan)

^b Seoul National University College of Medicine   (South Korea)

^c NATIONAL CANCER CENTER   (Japan)

^d National Cancer Center   (South Korea)

^e SHIZUOKA CANCER CENTER   (Japan)

^f Ajou University School of Medicine   (South Korea)

^g TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^h Yonsei University College of Medicine   (South Korea)

ⁱ Hakodate Goryokaku Hospital   (Japan)

^j KANAGAWA CANCER CENTER   (Japan)

^k The Catholic University of Korea   (South Korea)

^l OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^m HYOGO COLLEGE OF MEDICINE   (Japan)

ⁿ Kaizuka City Hospital   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CARDIOPULMONARY ARREST; CONTROLLED STUDY; DIARRHEA; DRUG FATALITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTRECTOMY; HAND FOOT SYNDROME; HIGH RISK POPULATION; HUMAN; HYPONATREMIA; INTENTION TO TREAT ANALYSIS; JAPAN; LAPAROTOMY; LEUKOPENIA; LIVER METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; OPERATION DURATION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARAAORTIC LYMPH NODE; PERITONEUM METASTASIS; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SINGAPORE; SOUTH KOREA; STOMACH CANCER; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING; ADJUVANT CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR INVASION; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GASTRECTOMY; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; REPUBLIC OF KOREA; RISK ASSESSMENT; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84960491338     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00553-7     Document Type: Article

References (30)

1. Hartgrink HH, Putter H, Kranenbarg EK, Bonenkamp JJ, van de Velde CJH Value of palliative resection in gastric cancer. Br J Surg 2002, 89:1438-1443. for the Dutch Gastric Cancer Group.
2. Bonenkamp JJ, Sasako M, Hermans J, van de Velde CJH Tumor load and surgical palliation in gastric cancer. Hepatogastroenterology 2001, 48:1219-1221.
3. Kikuchi S, Arai Y, Morise M, et al. Gastric cancer with metastases to the distant peritoneum: a 20-year surgical experience. Hepatogastroenterology 1998, 45:1183-1188.
4. Ouchi K, Sugawara T, Ono H, et al. Therapeutic significance of palliative operations for gastric cancer for survival and quality of life. J Surg Oncol 1998, 69:41-44.
5. Maekawa S, Saku M, Maehara Y, et al. Surgical treatment for advanced gastric cancer. Hepatogastroenterology 1996, 43:178-186.
6. Haugstvedt T, Viste A, Eide GE, Real C, Soreide O The survival benefit of resection in patients with advanced stomach cancer: the Norwegian multicenter experience. World J Surg 1989, 13:617-622. Members of the Norwegian stomach cancer trial.
7. Bozzetti F, Bonfanti G, Audisio RA, et al. Prognosis of patients after palliative surgical procedures for carcinoma of the stomach. Surg Gynecol Obstet 1987, 164:151-154.
8. Meijer S, De Bakker OJ, Hoitsma HF Palliative resection in gastric cancer. J Surg Oncol 1983, 23:77-80.
9. Koga S, Kawaguchi H, Kishimoto H, et al. Therapeutic significance of noncurative gastrectomy for gastric cancer with liver metastasis. Am J Surg 1980, 140:356-359.
10. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008, 9:215-221.
11. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008, 358:36-46. for the Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom.
12. Boku N, Yamamoto S, Fukuda H, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 2009, 10:1063-1069. for the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group.
13. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376:687-697.
14. Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011, 29:3968-3976.
15. Lee J, Lim T, Uhm JE, et al. Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol 2007, 18:886-891.
16. Pozzo C, Ohashi Y Meta-analysis of randomized trials assessing the influence of chemotherapy and prognostic factor in advanced/recurrent gastric cancer. Proc Am Soc Clin Oncol 2009, 27(suppl 15):4550. on behalf of the GASTRIC project, (abstr).
17. Koo DH, Ryoo BY, Kim HJ, et al. A prognostic model in patients who receive chemotherapy for metastatic or recurrent gastric cancer: validation and comparison with previous models. Cancer Chemother Pharmacol 2011, 68:913-921.
18. Takahari D, Boku N, Mizusawa J, et al. Determination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan Clinical Oncology Group 9912. Oncologist 2014, 19:358-366.
19. Mahar AL, Coburn NG, Singh S, Law C, Helyer LK A systematic review of surgery for non-curative gastric cancer. Gastric Cancer 2012, 15(suppl 1):S125-S137.
20. Japanese classification of gastric carcinoma, 2nd English edn. Gastric Cancer 1998, 1:10-24. Japanese Gastric Cancer Association.
21. Lan KKG, DeMets DL Discrete sequential boundaries for clinical trials. Biometrika 1983, 70:659-663.
22. DeMets DL, Lan KKG Interim analysis: the alpha spending function approach. Stat Med 1994, 13:1341-1352.
23. Spiegelhalter DJ, Freedman LS, Parmar MKB Applying Bayesian ideas in drug development and clinical trials. Stat Med 1993, 12:1501-1517.
24. Aoyama T, Kawabe T, Fujikawa H, et al. Loss of lean body mass as an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer. Ann Surg Oncol 2015, 22:2560-2566.
25. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006, 355:11-20.
26. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001, 358:966-970. for the European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group.
27. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001, 345:1655-1659.
28. Tarantino I, Warschkow R, Worni M, et al. Prognostic relevance of palliative primary tumor removal in 37,793 metastatic colorectal cancer patients: a population-based, propensity score-adjusted trend analysis. Ann Surg 2015, 262:112-120.
29. Rahbari NN, Lordick F, Fink C, et al. Resection of the primary tumour versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases (UICC stage IV): SYNCHRONOUS-a randomised controlled multicentre trial (ISRCTN30964555). BMC Cancer 2012, 12:142. for the SYNCHRONOUS trial group.
30. Kerkar SP, Kemp CD, Duffy A, et al. The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone. Trials 2009, 10:121.